站内搜索
最新录用更多>>
双特异性抗体药物在肿瘤治疗领域的研究进展
    点此下载全文
引用本文:岳雅丽,尹骏,高向东,姚文兵.双特异性抗体药物在肿瘤治疗领域的研究进展[J].中国药科大学学报,2019,50(3):289-298.
Cite:YUE Yali,YIN Jun,GAO Xiangdong,YAO Wenbing.Research advances of bispecific antibody drugs in tumor therapy[J].J China Pharm Univ,2019,50(3):289-298.
摘要点击次数: 593
全文下载次数: 926
作者单位
岳雅丽 中国药科大学江苏省生物药物成药性研究重点实验室生命科学与技术学院 
尹骏 中国药科大学江苏省生物药物成药性研究重点实验室生命科学与技术学院 
高向东 中国药科大学江苏省生物药物成药性研究重点实验室生命科学与技术学院 
姚文兵 中国药科大学江苏省生物药物成药性研究重点实验室生命科学与技术学院 
中文摘要:肿瘤免疫疗法是目前治疗肿瘤的新方向。双特异性抗体可结合两种不同的抗原,因而在肿瘤治疗领域的开发前景十分广阔。双特异性抗体中最引人注目的三功能抗体和双特异性T细胞衔接抗体已分别有药物上市,代表药物是卡妥索单抗和博纳吐单抗。迄今为止,有将近100种抗肿瘤的双特异性抗体药物正在进行临床研究,深入理解它们的作用机制将为肿瘤治疗提供更多可行的方案。本文对卡妥索单抗、博纳吐单抗和目前极具开发前景的双特异性抗体药物的研究进展进行综述,以期为在肿瘤治疗领域的开发与应用奠定基础。
中文关键词:双特异性抗体  抗肿瘤  卡妥索单抗  博纳吐单抗  进展
 
Research advances of bispecific antibody drugs in tumor therapy
Abstract:Tumor immunotherapy is currently the new direction for the treatment of cancer. Bispecific antibody can bind two different antigens, so the development prospect in the field of tumor treatment is very attractive. The most compelling trifunctional antibody and bispecific T-cell engager in bispecific antibodies have been marketed separately, with representative drugs as catumaxomab and blinatumomab, respectively. So far, nearly 100 antitumor bispecific antibody drugs are undergoing clinical trials and in-depth understanding of their mechanisms of action will provide more powerful solutions for cancer treatment. This review summarizes the progress of catumaxomab, blinatumomab and current highly promising bispecific antibody drugs, for the further development and application of tumor therapy.
keywords:bispecific antibody  antitumor  catumaxomab  blinatumomab  progress
查看全文  查看/发表评论  下载PDF阅读器
分享按钮